PE20030772A1 - Derivados de pirimidina - Google Patents

Derivados de pirimidina

Info

Publication number
PE20030772A1
PE20030772A1 PE2002000834A PE2002000834A PE20030772A1 PE 20030772 A1 PE20030772 A1 PE 20030772A1 PE 2002000834 A PE2002000834 A PE 2002000834A PE 2002000834 A PE2002000834 A PE 2002000834A PE 20030772 A1 PE20030772 A1 PE 20030772A1
Authority
PE
Peru
Prior art keywords
aryl
alkyl
cycloalkyl
cyane
ilmethyl
Prior art date
Application number
PE2002000834A
Other languages
English (en)
Inventor
Eva Altmann
Kenji Hayakawa
Genji Iwasaki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121024A external-priority patent/GB0121024D0/en
Priority claimed from GBGB0121026.9A external-priority patent/GB0121026D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20030772A1 publication Critical patent/PE20030772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN DERIVADO DE PIRIMIDINA DE FORMULA I DONDE R ES H, -R4-, OR4, NR3R4 DONDE R3 ES H, ALQUILO, CICLOALQUILO DE 3 A 10 ATOMOS DE CARBONO; R4 ES ALQUILO, CICLOALQUILO CON MOLECULA DE 3 A 10 ATOMOS DE CARBONO, ENTRE OTROS; R1 ES -CO-NR5R6, -NH-CO-R5, -CH2-NH-C(O)-R5, ENTRE OTROS; R5 ES ARILO, ARILO-ALQUILO, CICLOALQUILO DE 3-10 ATOMOS; R6 ES H, ARILO, ARILO-ALQUILO, ARILO-ALQUENILO, CICLOALQUILO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA ELABORACION Y COMPUESTOS INTERMEDIOS. SON COMPUESTOS PREFERIDOS N-[2-CIANO-4-(2,2-DIMETIL-PROPILAMINO)-PIRIMIDIN-5-ILMETIL]-2-(4-METOXI-FENIL)-ACETAMIDA, N-[2-CIANO-4-(2,2-DIMETIL-PROPILAMINO)-PIRIMIDIN-5-ILMETIL]-2-(4-METOXI-FENIL)-ACETAMIDA, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA CATEPSINA K Y SON UTILES PARA EL TRATAMIENTO DE INFLAMACION, ARTRITIS REUMATOIDE
PE2002000834A 2001-08-30 2002-08-29 Derivados de pirimidina PE20030772A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0121024A GB0121024D0 (en) 2001-08-30 2001-08-30 Organic compounds
GBGB0121026.9A GB0121026D0 (en) 2001-08-30 2001-08-30 Organic compounds

Publications (1)

Publication Number Publication Date
PE20030772A1 true PE20030772A1 (es) 2003-10-02

Family

ID=26246490

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000834A PE20030772A1 (es) 2001-08-30 2002-08-29 Derivados de pirimidina

Country Status (22)

Country Link
US (2) US7112589B2 (es)
EP (1) EP1423121B1 (es)
JP (1) JP4131701B2 (es)
KR (1) KR100629834B1 (es)
CN (1) CN1549717B (es)
AR (1) AR036375A1 (es)
AT (1) ATE345136T1 (es)
AU (1) AU2002333758B2 (es)
BR (1) BR0212141A (es)
CA (1) CA2456127C (es)
CO (1) CO5560576A2 (es)
DE (1) DE60216122T2 (es)
ES (1) ES2275946T3 (es)
HU (1) HUP0401431A3 (es)
IL (1) IL160295A0 (es)
MX (1) MXPA04001930A (es)
NZ (1) NZ531287A (es)
PE (1) PE20030772A1 (es)
PL (1) PL208280B1 (es)
PT (1) PT1423121E (es)
RU (1) RU2326119C2 (es)
WO (1) WO2003020278A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201976D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
AU2004262903B2 (en) * 2003-07-21 2007-08-23 Novartis Ag Combinations of a Cathepsin K inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
JP2007506741A (ja) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド 向代謝性グルタミン酸受容体のピラゾール系調節剤
JP2007511548A (ja) * 2003-11-19 2007-05-10 ノバルティス アクチエンゲゼルシャフト 重篤な骨量減少疾患におけるカテプシンｋ阻害剤の使用
US20070232586A1 (en) * 2004-04-21 2007-10-04 Kazuyuki Ohmoto Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
TW200624429A (en) * 2004-09-07 2006-07-16 Glaxo Group Ltd Novel cysteine protease inhibitors
WO2006040300A1 (en) * 2004-10-12 2006-04-20 N.V. Organon 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
GB0514684D0 (en) * 2005-07-18 2005-08-24 Novartis Ag Organic compounds
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
WO2007025774A2 (en) * 2005-09-02 2007-03-08 Glaxo Group Limited Cysteine protease inhibitors
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
AU2007253796A1 (en) * 2006-05-22 2007-11-29 Velcura Therapeutics, Inc. Use of Cathepsin K antagonists in bone production
WO2007148064A1 (en) * 2006-06-23 2007-12-27 Astrazeneca Ab Pteridine derivatives and their use as cathespin inhibitors
EP1947091A1 (en) * 2007-01-16 2008-07-23 Glaxo Group Limited Pyrimidyl nitrile derivatives as cysteine protease inhibitors
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
PL2222636T3 (pl) 2007-12-21 2014-04-30 Ligand Pharm Inc Selektywne modulatory receptorów androgenowych (SARM) i ich zastosowania
JP5587790B2 (ja) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2316820A1 (en) * 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
WO2011086125A1 (en) 2010-01-15 2011-07-21 N.V. Organon 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
ES2721639T3 (es) 2010-10-06 2019-08-02 Inst Catalana Recerca Estudis Avancats Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
US8524710B2 (en) * 2010-11-05 2013-09-03 Hoffmann-La Roche Inc. Pyrrolidine derivatives
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
JP6386450B2 (ja) 2012-06-06 2018-09-05 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 肺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CA2888122A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
KR20150122731A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 예후 및 치료 방법
DK3055429T3 (en) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
EP3229909B1 (en) 2014-12-11 2020-10-14 Inbiomotion S.L. Binding members for human c-maf
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
WO2018138356A1 (en) * 2017-01-27 2018-08-02 Genfit Rorgamma modulators and uses thereof
CN108586356B (zh) * 2017-03-16 2021-02-19 杭州科巢生物科技有限公司 瑞博西尼新中间体及其制备瑞博西尼的合成方法
WO2019102380A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
CN109467536B (zh) * 2018-12-23 2020-06-05 沧州普瑞东方科技有限公司 2-氯/羟基嘧啶-5-羧酸的合成方法
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1251074B (de) 1960-11-02 1967-09-28 J R Geigy A -G , Basel (Schweiz) Selektives Herbizid
NL295648A (es) * 1962-07-26
BR6915234D0 (pt) 1969-05-22 1973-06-07 American Cyanamid Co Novos derivados de melamina e processo para sua preparaca
CH627919A5 (de) * 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
CA2230894A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
WO1997028128A1 (en) 1996-02-02 1997-08-07 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
DE60003702T2 (de) 1999-09-13 2004-04-22 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
HU225917B1 (en) * 1999-09-16 2007-12-28 Tanabe Seiyaku Co Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
MXPA02010693A (es) * 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
BR0212141A (pt) 2004-08-24
WO2003020278A1 (en) 2003-03-13
KR20040029101A (ko) 2004-04-03
KR100629834B1 (ko) 2006-09-29
PL367821A1 (en) 2005-03-07
DE60216122T2 (de) 2007-09-06
CA2456127C (en) 2009-10-20
IL160295A0 (en) 2004-07-25
US7112589B2 (en) 2006-09-26
RU2004109812A (ru) 2005-10-20
HUP0401431A2 (hu) 2004-10-28
DE60216122D1 (de) 2006-12-28
US20060074092A1 (en) 2006-04-06
RU2326119C2 (ru) 2008-06-10
EP1423121A1 (en) 2004-06-02
ATE345136T1 (de) 2006-12-15
PT1423121E (pt) 2007-02-28
EP1423121B1 (en) 2006-11-15
CA2456127A1 (en) 2003-03-13
HUP0401431A3 (en) 2004-11-29
CN1549717B (zh) 2011-08-17
JP2005505550A (ja) 2005-02-24
AR036375A1 (es) 2004-09-01
JP4131701B2 (ja) 2008-08-13
CO5560576A2 (es) 2005-09-30
US20040249153A1 (en) 2004-12-09
NZ531287A (en) 2005-12-23
PL208280B1 (pl) 2011-04-29
AU2002333758B2 (en) 2006-01-19
CN1549717A (zh) 2004-11-24
MXPA04001930A (es) 2004-06-15
ES2275946T3 (es) 2007-06-16

Similar Documents

Publication Publication Date Title
PE20030772A1 (es) Derivados de pirimidina
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
DK0783486T3 (da) Hidtil ukendte prostaglandinsynthaseinhibitorer
HUP0100287A2 (hu) Rákellenes hatású tienopirimidin- és tienopiridin-származékok
IS6309A (is) Kínasólínafleiður
PT96890A (pt) Processo para a preparacao de novos derivados com estrutura naftalenica e de composicoes farmaceuticas que os contem
EA200401172A1 (ru) Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии
NO20044038L (no) Glutaminylbaserte DRIV-inhibitorer
AR004195A1 (es) Nuevos derivados de la 5-0 desosaminil-6-0-metil-eritronolida a, su procedimiento de preparacion, compuestos intermediarios, metodo de aplicacionde los mismos para la preparacion de productos biologicamente activos.
DE69705480T2 (de) Verwendung von Oestrogenagonisten und -antagonisten zur Herstellung eines Medikaments zur Behandlung von Atherosklerose, unabhängig von Lipidsenkung
DE60325830D1 (de) Substituiertes phenylalkansäurederivat und dessen verwendung
ES2253568T3 (es) Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias.
PE14696A1 (es) Derivado de fenetanolamina
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
EA199801006A1 (ru) Бициклические амины в качестве инсектицидов
AR018596A1 (es) Compuestos azapoliciclicos fusionados con arilo utiles en el tratamiento de desordenes neurologicos y fisiologicos, composiciones farmaceuticas,metodos de tratamiento que los utilizan
EA200500984A1 (ru) Производные 3-замещённого-4-пиримидона
FI940731A (fi) Amiditetratsolit ACAT-inhibiitoreina
ES2069112T3 (es) Derivados de acido hidroxamico biciclico sustituidos con sulfonilamino.
ES2087019B1 (es) Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
KR960022476A (ko) 디페닐 디설파이드 화합물
ATE460425T1 (de) Histondeacetylaseinhibitor und verfahren zu dessen herstellung
AR037140A1 (es) Un compuesto de aminopirrol, su utilizacion, un procedimiento para producirlo y una composicion que lo comprende
EA200200749A1 (ru) Производные гетероциклического амида

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed